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OBJECTIVE—Inhibition of the Na
+-glucose cotransporter type
2 (SGLT2) is currently being pursued as an insulin-independent
treatment for diabetes; however, the behavioral and metabolic
consequences of SGLT2 deletion are unknown. Here, we used
a SGLT2 knockout mouse to investigate the effect of increased
renal glucose excretion on glucose homeostasis, insulin sensitiv-
ity, and pancreatic b-cell function.
RESEARCH DESIGN AND METHODS—SGLT2 knockout
mice were fed regular chow or a high-fat diet (HFD) for 4 weeks,
or backcrossed onto the db/db background. The analysis used
metabolic cages, glucose tolerance tests, euglycemic and hyper-
glycemic clamps, as well as isolated islet and perifusion studies.
RESULTS—SGLT2 deletion resulted in a threefold increase in
urine output and a 500-fold increase in glucosuria, as well as
compensatory increases in feeding, drinking, and activity. SGLT2
knockout mice were protected from HFD-induced hyperglycemia
and glucose intolerance and had reduced plasma insulin concen-
trations compared with controls. On the db/db background,
SGLT2 deletion prevented fasting hyperglycemia, and plasma
insulin levels were also dramatically improved. Strikingly, pre-
vention of hyperglycemia by SGLT2 knockout in db/db mice pre-
served pancreatic b-cell function in vivo, which was associated
with a 60% increase in b-cell mass and reduced incidence of b-cell
death.
CONCLUSIONS—Prevention of renal glucose reabsorption by
SGLT2 deletion reduced HFD- and obesity-associated hypergly-
cemia, improved glucose intolerance, and increased glucose-
stimulated insulin secretion in vivo. Taken together, these data
support SGLT2 inhibition as a viable insulin-independent treat-
ment of type 2 diabetes. Diabetes 60:890–898, 2011
T
reatments of type 2 diabetes must balance the
prevention of microvascular complications with
the minimization of clinically signiﬁcant hy-
poglycemia. The difﬁculty in safely achieving
these goals, combined with epidemic increases in diabetes
worldwide, has spurred the search for novel therapeutic
strategies. Among these, inhibition of the Na
+-glucose
cotransporter type 2 (SGLT2) has emerged as a promising
therapy (1,2). SGLT2 is a member of the SLC5 gene family
and transports glucose across cells using the Na
+ gradient
established by Na
+-K
+-ATPases (3). SGLT2 is a low-afﬁnity,
high-capacity transporter expressed predominantly in the
early proximal tubule of the kidney and accounts for about
90% of renal glucose reabsorption (4–6). Given that the
kidney ﬁlters approximately 180 g of glucose daily, SGLT2
inhibition may not just reduce hyperglycemia but may also
promote negative energy balance and weight loss.
Type 2 diabetes is characterized by fasting hyperglyce-
mia as a result of insulin resistance, but is often preceded
by hyperinsulinemia and normal blood glucose levels,
a state that is maintained by compensatory insulin secre-
tion by the pancreatic b-cell (7). The ability of the b-cell to
counteract an increased glucose load is short-lived, how-
ever, and eventually pancreatic islets fail, giving rise to
hyperglycemia. Rodent and human studies have both
shown that glucose toxicity is implicated in b-cell failure
by increasing the rate of b-cell death by the induction of
proapoptotic genes (8–10). Inhibition of SGLT2 therefore
has the potential to not only acutely lower hyperglycemia
but to also improve glucose homeostasis by reducing glu-
cose toxicity and preventing islet failure.
Despite recent interest in SGLT2 as a potential target
for diabetes treatment, relatively few long-term models of
SGLT2 deﬁciency have been characterized. Previously,
nonselective inhibition of both SGLT1 and SGLT2 for 4
weeks in partially pancreatomized diabetic rats by injection
of phlorizin led to increases in insulin sensitivity and insulin
secretion (11,12). More recently, improvements in glucose
homeostasis were demonstrated in diabetic rodent models
after treatment with SGLT2-speciﬁc inhibitors for periods
of 2 to 9 weeks (13–16). As many as seven different SGLT2
inhibitors designed for use in humans have been charac-
terized in cell culture and animal studies, and many of
these have moved on to clinical trials (2,17–22). Here, we
describe the ﬁrst in vivo characterization of glucose ho-
meostasis in a SGLT2 knockout mouse model. We inves-
tigated the behavioral and metabolic consequences of
SGLT2 deletion, and furthermore, we determined the ef-
fect of renal glucose excretion on glucose homeostasis,
insulin sensitivity, and b-cell function in the context of
both high-fat feeding and genetically determined obesity
(db/db) and diabetes.
RESEARCH DESIGN AND METHODS
Animals and diets. The SGLT2 (Slc5a2)d e ﬁcient mice were generated by
Lexicon Pharmaceuticals, Inc. (The Woodlands, TX) as previously described
(6). SGLT2 and db/db backcrosses were performed at The Jackson Laboratory
(Bar Harbor, ME) and shipped to Yale for studies. Mice were housed at Yale
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ORIGINAL ARTICLEUniversity School of Medicine and maintained in accordance with the In-
stitutional Animal Care and Use Committee guidelines. Mice were housed at
22 6 2°C on a 12-h light/dark cycle with free access to food and water. Mice
were fed regular chow (RC; 18% fat, 58% carbohydrate, 24% protein by calo-
ries; TD2018; Harlan Teklad, Madison, WI) or 4 weeks of high-fat diet (HFD;
55% fat, 24% carbohydrate, 21% protein by calories; TD93075; Harlan Teklad).
Body composition was determined by
1H magnetic resonance spectroscopy
(Bruker Minispec). The Comprehensive Laboratory Animal Monitoring System
(Columbus Instruments, Columbus, OH) was used to evaluate activity, energy
expenditure, feeding, drinking, and respiratory quotient over the course of 48
h. Data are the 24-h average normalized to body weight. For the urine col-
lection studies, mice were housed for 24 h with free access to food and water
in wire-bottomed cages designed to separate and collect urine and feces.
In vivo glucose homeostasis. Glucose tolerance tests were performed after
an overnight fast. Mice were injected intraperitoneally with 1 mg/kg glucose,
and bloodwas collected bytail bleedat set times for plasma insulin and glucose
measurements. Hyperinsulinemic euglycemic clamps were performed as pre-
viously described (23), with minor modiﬁcations. Speciﬁcally, clamp duration
was extended to 180 min and the insulin dose was increased to 20 mU $ kg
21 $
min
21. Hyperglycemic clamps were conducted after an overnight fast. Mice
were given a primed/variable infusion of glucose to reach and maintain hy-
perglycemia during the 120-min experiment. Blood was collected at set
intervals by tail bleeds for determination of plasma glucose and insulin. Be-
cause of differences in fasting plasma glucose and insulin levels between
genotypes, infusion rates were chosen to achieve matched changes in plasma
glucose (D glucose), and the change in plasma insulin from baseline (D in-
sulin) was used to assess the pancreatic b-cell response.
Pancreas and islet studies. Isolated islet studies were conducted as pre-
viously described (24). In brief, pancreata were removed from anesthetized
mice and minced in CMRL media with type P collagenase to disperse cells.
Islets were hand picked under a light microscope and allowed to recover
overnight in media. Eighty islets were picked and loaded into a perifusion
chamber with acrylamide gel column beads (Bio-Gel P4G; Bio-Rad, Hercules,
CA) and perfusion buffer (Krebs-Ringer buffer with 3 mmol/L glucose and 0.2%
fatty acid-free BSA). Perifusions were conducted with a Bio-Rep (Miami, FL)
perifusion instrument that allows for precise temperature and ﬂow control and
collection of samples into 96-well format. After a 1-h equilibration period,
islets were perifused with the indicated agonists, and samples were collected
at 1-min intervals for 40 min. At the end of the perifusion, islet DNA was
isolated and quantiﬁed for normalization of insulin and glucagon data using
a Picogreen dsDNA quantitation kit (Invitrogen) according to the manu-
facturer’s instructions.
Preparation and staining of all histologic samples were conducted at the
Department of Pathology Histology Core at Yale. Samples were ﬁxed in 4%
formalin overnight and set in parafﬁn wax. Sections were cut at 5 mm, dried,
deparaﬁnized, and rehydrated with distilled water. For kidney studies, he-
matoxylin and eosin (H&E) stains were analyzed in a blinded fashion by
a pathologist. For pancreas studies, transferase-mediated dUTP nick-end la-
beling (TUNEL) reaction was performed according to the manufacturer’s
instructions (Millipore S7100; Millipore, Billerica, MA), after which slides were
incubated with polyclonal anti-insulin (Dako 0564) and visualized by an alkaline-
phosphatase–based method (Dako K5355).
Frequency of cell death was calculated as the number of insulin/TUNEL-
positive cells corrected by relative islet area (islet area/pancreas area) for 10 to
15ﬁeldspersectionandthreesectionspermouse.Isletnumberwasdetermined
by counting all islets within a given ﬁeld, corrected to pancreas area. Ap-
proximately 30 ﬁelds were taken at random, and three sections per mouse were
analyzed. Sections were staggered to reduce the possibility of analyzing the
same islet twice. For proliferationstudies, slides were incubated with anti-Ki-67
(Biocare Medical CRM325) and anti-insulin (Dako A0564) and visualized with
peroxidase and ﬂuorescent secondary antibodies (Dako K4003, Invitrogen
A11073). Frequency of cellular proliferation was calculated in a similar fashion
as frequency of cell death. Pancreas weights were not available, so relative
b-cell volume was calculated as the ratio of islet area/pancreas area. Cell size
measurements were made using ImageJ software.
Biochemical analyses. Plasma and urine glucose concentrations were mea-
sured by a glucose oxidase method using a Beckman Glucose Analyzer II.
Plasma insulin was measured by radioimmunoassay kit (Linco Research,
St. Louis, MO), and fatty acids were measured by a spectrophotometric tech-
nique (Wako NEFA Kit, Osaka, Japan). Hepatic glycogen content was measured
as previously described, except that a 10:1 volume/weight dilution was used for
homogenization (25). Insulin and glucagon from isolated islets were measured
with the LINCOplex platform (Millipore). Plasma chemistries were measured
with a Roche COBAS Mira automated chemistry analyzer at the Yale Mouse
Metabolic Phenotyping Center Analytical Core. Plasma creatinine levels were
determined by high-performance liquid chromatography/mass spectrometry/
mass spectrometry.
Statistical analysis. Data are reported as the mean 6 SEM. Comparisons
between groups were made using unpaired, two-tailed Student t tests. For time
course data, two-way and one-way ANOVA were used where appropriate. A
value of P , 0.05 was considered signiﬁcant. Statistical analyses were per-
formed using GraphPad Prism 5 software.
RESULTS
Phenotype of SGLT2
2/2 RC- and HFD-fed mice. The
RC-fed SGLT2
2/2 mice weighed approximately 10% less
than wild-type (WT) mice at age 16 weeks (Table 1). To
determine the effect of SGLT2 deletion in the presence of
increased body weight and adiposity, a second group of
SGLT2
2/2 and WT mice were fed an HFD for 4 weeks. HFD
mice had an increased body weight compared with con-
trols for both genotypes, but unlike RC-fed mice, HFD/
SGLT2
2/2 mice only trended toward a lower body weight
(P = 0.12; Table 1). There were no differences in fat mass
between RC/WT and RC/SGLT2
2/2 mice, and HFD/
SGLT2
2/2 animals trended toward reduced adiposity
(P = 0.08; Table 1).
Daily urine volume was 4.5-fold greater in SGLT2
2/2
than in WT mice, which translated to a 500-fold increase in
glucosuria, with similar ﬁndings in the HFD mice (Table 1).
Despite increased urine volume and glucosuria, plasma
chemistries were unchanged in SGLT2
2/2 mice (Supple-
mentary Table 1), in agreement with a recently published
description of the SGLT2 knockout model (6). There was
no difference in the blood urea nitrogen (BUN)/creatinine
ratio between WT or SGLT2
2/2 mice, suggesting that
volume depletion could not account for the lower weight
(Supplementary Table 1). Histologic analysis of kidney
sections revealed normal glomerular structures and tu-
bulointerstitial compartments, without signiﬁcant histo-
pathologic changes in the proximal or distal nephron of
SGLT22/2 mice (Supplementary Fig. 1), and there was no
difference in kidney weight between genotypes (Table 1).
TABLE 1
Physiologic overview of SGLT2
2/2 mice
Body weight Body fat Kidney weight Plasma BUN Plasma creatinine Urine output Glucosuria
Mouse (g) (%) (mg/g) (mg/dL) (mg/dL) (mL/day) (mg/day)
WT 29.4 6 0.7 6.9 6 0.7 6.55 6 0.42 23.2 6 0.3 0.074 6 0.001 1.5 6 0.3 0.9 6 0.3
SGLT2
2/2 26.7 6 0.6* 7.4 6 0.3 6.49 6 0.14 23.8 6 1.1 0.077 6 0.007 6.7 6 0.4† 502 6 30†
HFD/WT 35.0 6 0.7 26.4 6 1.2 ND 20.8 6 0.7 0.103 6 0.005 1.7 6 0.2 1.0 6 0.3
HFD/SGLT2
2/2 33.0 6 1.0 22.3 6 1.9 ND 18.8 6 0.7 0.119 6 0.007 5.4 6 0.5† 431 6 31†
Data were collected from 16-week-old, ad libitum fed mice. Kidney weight represents the weight of one kidney corrected by body weight. Mice
were housed in custom cages for 24 h for urine output and glucosuria measurements. HFD was fed for 4 weeks. n =1 2 –16 per genotype for
body weight and fat data; n =6 –8 for remaining data. *P , 0.05; †P , 0.001 for comparison of WT with SGLT2
2/2 for each diet. Data analyzed
by Student t test. ND, not done.
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metabolism and behavior, SGLT2
2/2 and WT mice were
housed in metabolic cages. During resting hours (light cy-
cle), there was no difference in activity, energy expenditure,
or food intake between genotypes (Supplementary Fig. 2A–
C), although water intake was elevated during this time for
SGLT2
2/2 mice (Supplementary Fig. 2D). In contrast, there
were marked differences in each parameter between mice
during active hours (dark cycle). Activity, energy expendi-
ture, and food and water intake were all signiﬁcantly in-
creased in SGLT2
2/2 mice during the dark cycle (Fig. 1A).
Notably, there was a 20% increase in feeding and a 190%
increase in drinking compared with controls. Despite the
increase in caloric intake, SGLT2
2/2 mice maintained a
lower body weight through a combination of 7% higher
energy expenditure during the dark cycle and 13% (1.9 kcal/
day) caloric loss of carbohydrate in the urine.
Under HFD conditions, mice consume signiﬁcantly less
carbohydrate. Interestingly, unlike RC-fed mice, there
were no differences in activity, energy expenditure, or
food intake in the light or dark cycle during HFD (Sup-
plementary Fig. 3), consistent with the lower carbohydrate
composition of the chow. Drinking, however, was clearly
increased relative to HFD controls throughout the day,
reﬂecting continuous glucose loss. In comparison with
RC/SGLT2
2/2 mice, HFD/SGLT2
2/2 mice had lower water
consumption (36.9 6 2.5 vs. 45.6 6 2.9 mL/h; P , 0.05) and
urine output (5.2 6 0.5 vs. 6.5 6 0.4 mL/day; P , 0.05),
again suggesting that carbohydrate content of the chow
had a large inﬂuence on glucosuria.
The lower respiratory quotient in SGLT2
2/2 mice (Fig. 1A)
reﬂects a higher rate of lipid relative to carbohydrate oxi-
dation, as might be expected for mice that are carbohydrate-
depleted by profound glucosuria. Indeed, there was a 2.5-fold
decrease in hepatic glycogen content in SGLT2
2/2 com-
p a r e dw i t hW Tm i c e( 5 . 16 1.1 vs. 12.7 6 2.0 mg/mg tis-
sue; P , 0.05). This was even more dramatic on the HFD,
where the respiratory quotient was 0.78 and approached
that of nearly a complete dependence on lipid oxidation
(Supplementary Fig. 3E).
Glucose homeostasis is improved in RC- and HFD-fed
SGLT2
2/2 mice. Next, in vivo glucose homeostasis was
assessed. Compared with RC/WT mice, RC/SGLT2
2/2 mice
had signiﬁcantly lower fasting plasma glucose concen-
trations and a nonsigniﬁcant reduction in plasma insulin
concentrations (9.0 6 0.6 and 6.4 6 1.8 mU/mL insulin; P =
0.17; Fig. 1B and C). After 4 weeks of the HFD, fasting
glucose was drastically reduced in SGLT
2/2 compared
with WT mice and was indistinguishable from RC/WT
controls (Fig. 1B). Plasma insulin concentrations were 50%
lower in the HFD/SGLT2
2/2 compared with WT mice, as
would be expected for the lower plasma glucose levels.
HFD/SGLT2
2/2 mice had a twofold increase in fasting insulin
compared with RC/WT mice (Fig. 1C), suggesting that SGLT2
deletion did not completely prevent insulin resistance.
Intraperitoneal glucose tolerance tests (IPGTTs) were
performed to determine the effect of SGLT2 knockout on
glucose homeostasis. Plasma glucose concentrations
remained lower in SGLT2
2/2 than in WT mice for the en-
tire experiment (P , 0.01 by two-way ANOVA; Fig. 1D).
The area under the curve (AUC) for glucose was 20% lower
for SGLT2
2/2 than for WT mice (Fig. 1F). A similar, but
more pronounced effect was observed during HFD studies
(P , 0.001 by two-way ANOVA; Fig. 1D), where AUC
glucose was 40% less in SGLT2
2/2 mice and was indis-
tinguishable from WT/RC controls (Fig. 1F). Changes in
plasma insulin concentrations roughly mirrored the dif-
ferences observed for plasma glucose (WT vs. SGLT2
2/2
RC and HFD P , 0.01, two-way ANOVA; Fig. 1E), con-
sistent with appropriate b-cell function. The insulin AUC
was 37% less for RC/SGLT2
2/2 compared with RC/WT
mice, while after HFD, the insulin AUC was 53% less for
SGLT2
2/2 mice (Fig. 1G). Thus, loss of SGLT2 signiﬁcantly
improved basal and IPGTT-challenged glucose homeosta-
sis in RC- and HFD-fed mice.
SGLT2 deletion reduces adiposity and improves
glucose homeostasis in db/db mice. To determine
whether loss of SGLT2 was protective in the setting of
extreme obesity and insulin resistance, SGLT2
2/2 mice
were bred onto the db/db background. The db/db mice are
leptin receptor–deﬁcient and develop profound hyperpha-
gia, obesity, hypercorticosteronemia, insulin resistance,
and eventually, diabetes. At approximately age 18 weeks,
body weights were similar for both heterozygous (db/db-
SGLT2
+/2) and homozygous (db/db-SGLT2
2/2) SGLT2 de-
letion compared with controls (db/db-SGLT2
+/+; Fig. 2A),
whereas body fat was 5% less in db/db-SGLT2
2/2 mice
(Fig. 2B). There was a progressive effect of SGLT2 deletion
on urine volume, with db/db-SGLT2
2/+ having a 2.6-fold
and db/db-SGLT
2/2 having a fourfold increase (Fig. 2C).
The db/db mice displayed profound glucosuria, totaling
approximately 500 mg/day (Fig. 2D). Still, there was
a three- and 4.4-fold increase in db/db-SGLT2
2/+ and db/db-
SGLT2
2/2 mice, respectively, indicating that lowering the
renal glucose threshold had a progressive effect on glu-
cosuria (Fig. 2D). Astonishingly, total daily glucose loss for
db/db-SGLT2
2/2 mice was 2.2 g or 5% of the animals’ body
weight.
Despite increased glucosuria in db/db-SGLT2
+/2 mice,
only the db/db-SGLT2
2/2 mice had signiﬁcantly reduced
plasma glucose concentrations (Fig. 2E). Strikingly, this
75-mg/dL reduction normalized glycemia to the same level
as RC/WT mice (WT: 131 6 6 mg/dL vs. db/db-SGLT2
2/2:
124 6 8 mg/dL). Plasma insulin levels were 50% lower in
db/db-SGLT2
2/2 crosses (Fig. 2F), consistent with the
lower plasma glucose concentration. Plasma insulin levels
were 10-fold higher than RC/WT mice (WT: 9.0 6 0.6 mU/
mL vs. db/db-SGLT2
2/2: 112 6 13 mU/mL), indicating the
persistence of insulin resistance in the db/db model. Lastly,
SGLT2 deletion had no effect on plasma fatty acid levels in
db/db mice (Fig. 2G).
Euglycemic clamp studies were performed to evaluate
the effect of SGLT2 deletion on insulin sensitivity and tissue-
speciﬁc glucose metabolism. Because of extreme insulin
resistance in db/db mice, plasma glucose concentrations
were clamped at 150 mg/dL using a 20 mU $ kg
21 $ min
21
insulin infusion (Supplementary Fig. 4A–D). The glucose
infusion rate (GIR) was 2.7-times greater in db/db-SGLT2
2/2
than in db/db-SGLT2
+/+ mice (Table 2). Quantitative mea-
surement of glucosuria during the clamp was not possible
for control or db/db-SGLT2
+/2 mice because of small urine
volumes, but ranged from 0 to 15% of total GIR for db/db-
SGLT2
2/2 mice (data not shown). Thus, the higher GIR
could only partially be accounted for by loss as glucosuria
and suggested improvements in insulin sensitivity. There was
no difference in whole-body or tissue-speciﬁc glucose uptake
in any group (Table 2), but clamped endogenous glucose
production was modestly reduced in db/db-SGLT2
2/2
compared with db/db-SGLT2
+/+ mice (Table 2).
Pancreatic b-cell function is preserved in db/db-
SGLT2
2/2 mice. Because glucose toxicity can lead to b-
cell failure, we assessed glucose-stimulated insulin secretion
SGLT2 KNOCKOUT PREVENTS b-CELL FAILURE
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trations varied among genotypes (Fig. 2E); therefore, all mice
were clamped 200 mg/dL above their basal plasma glucose
levels. Similar to euglycemic clamps, the GIR required to
maintain hyperglycemia for db/db-SGLT2
2/2 mice was
approximately twofold greater than for controls (Fig. 3A).
The total increase in plasma glucose concentrations above
baseline during the clamp was similar for all three groups
(Fig. 3B and C). No ﬁrst-phase insulin response was ob-
served, consistent with compromised islet function in db/db
FIG. 1. SGLT2
2/2 mice are protected from HFD-induced hyperglycemia and glucose intolerance. A: Dark cycle averages are shown for metabolic
cage data for activity, energy expenditure (EE), feeding, drinking, and respiratory quotient (VCO2/VO2) for WT and SGLT2
2/2 mice. B: Fasting
plasma glucose values for RC and HFD WT and SGLT2
2/2 mice. C: Fasting plasma insulin values. D: Changes in plasma glucose following in-
traperitoneal injection of 1-mg/kg glucose (WT vs. SGLT2
2/2 P < 0.01 for RC and P < 0.001 for HFD). E: Changes in plasma insulin levels during
experiment shown in D (WT vs. SGLT2
2/2 P < 0.01 for RC and HFD). F: AUC for glucose calculated from data in D. G: AUC for insulin calculated
from data in E. n =8 –12 mice per group. Data were analyzed by unpaired, two-tailed Student t test. Signiﬁcance between curves was determined by
two-way ANOVA. *P < 0.05, **P < 0.01, and ***P < 0.001. Data represent the mean 6 SEM.
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in plasma glucose concentration (DAUC glucose, Fig. 3C),
db/db-SGLT2
2/2 mice displayed a signiﬁcant increase in
absolute plasma insulin levels during the clamp (P , 0.001,
one-way ANOVA; Fig. 3D), and DAUC insulin was 2.4-fold
greater compared with db/db-SGLT2
+/+ mice (Fig. 3E).
Calculation of the change in plasma insulin (D insulin) from
baseline also demonstrated an approximate twofold in-
crease in glucose-stimulated insulin secretion for db/db-
SGLT2
2/2 compared with db/db-SGLT2
+/+ mice (Fig. 3F).
Thus, the greater than 10-fold increase in insulin secretion
for db/db-SGLT2
2/2 compared with the modest ﬁvefold in-
crease for controls during the hyperglycemic clamp was
consistent with improved b-cell function in vivo.
Isolated pancreatic islets from the db/db-SGLT2
+/+ and
db/db-SGLT2
2/2 mice were perifused to determine if
changes in individual islet function had occurred. During
isolation, islet yield was much greater for db/db-SGLT2
2/2
mice, so islets of similar size were selected for comparison.
Surprisingly, there was no difference in glucose-stimulated
FIG. 2. Increased glucosuria is associated with decreased fasting plasma glucose and insulin in db/db-SGLT2
2/2 mice. A: Body weights are shown
for db/db-SGLT
+/+, db/db-SGLT2
+/2, and db/db-SLGT2
2/2 mice at approximately 18 weeks of age. B: Percentage of body fat determined by proton
nuclear magnetic resonance. C: Urine volume at 24 h. D: Glucosuria at 24 h (n =5 –6 per group). E: Fasting plasma glucose level. F: Insulin levels. G:
Plasma fatty acid concentrations from overnight fasted mice. n =7 –9 per group; n =1 5 –20 per genotype except where noted. Data were analyzed by
Student t test. *P < 0.05, **P < 0.01, and ***P < 0.001. Data represent the mean 6 SEM.
TABLE 2
Hyperinsulinemic euglycemic clamp studies
Mouse
Plasma
glucose
(mg/dL)
Glucose
infusion rate
(mg $ kg
21 $
min21)
Endogenous
glucose
production
(mg $ kg
21 $
min21)
Whole-body
glucose
uptake
(mg $ kg
21 $
min21)
Skeletal muscle
glucose uptake
(nmol $ g
21 $
min21)
White adipose
glucose uptake
(nmol $ g
21 $
min21)
Insulin
(mU/mL)
db/db
SGLT2
+/+ 149 6 13 2.9 6 0.8 21.3 6 1.2 24.1 6 0.9 135 6 22 24.7 6 1.8 1211 6 138
SGLT2
+/2 152 6 18 3.9 6 1.2 19.3 6 1.9 23.3 6 1.2 134 6 18 27.1 6 2.2 1178 6 105
SGLT2
2/2 139 6 8 8.0 6 0.8* 16.2 6 2.1† 24.2 6 1.9 109 6 18 25.2 6 3.4 1268 6 158
Whole-body and tissue-speciﬁc glucose metabolism during hyperinsulinemic infusion. The db/db-SGLT2
+/+ (n = 9), db/db-SGLT2
+/2 (n = 8),
and db/db-SGLT2
2/2 (n = 7). Data analyzed by Student t test. *P , 0.01; †P , 0.05 compared with db/db-SGLT2
+/+.
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P = 0.37; Fig. 4A) or glucagon suppression (0.28 6 0.12
vs. 0.15 6 0.04 AUC glucagon; P =0 . 3 5 ;F i g .4 B) between
groups, suggesting that individual islet function, per se,
could not account for the observed in vivo differences.
Perifusion studies conducted for WT and SGLT
2/2
mice on RC and HFD also demonstrated no differences
in insulin or glucagon secretion (Supplementary Fig. 5A–D).
The difference between hyperglycemic clamp and islet
perifusion results suggested that changes in b-cell mass
might account for the increased insulin secretion observed
in vivo. Compared with RC/WT mice, relative b-cell vol-
ume was increased 3.3- and 5.4-fold for db/db-SGLT2
+/+
and db/db-SGLT2
2/2 mice, respectively, suggesting com-
pensatory hypertrophy as a result of insulin resistance
(1.06 6 0.12, 3.52 6 0.52, and 5.77 6 0.21 islet area/pancreas
area; P , 0.001 by one-way ANOVA). Importantly, there was
a 63% increase in relative b-cell volume in db/db-SGLT2
2/2
compared with db/db-SGLT2
+/+ mice (Fig. 4C and G). The
difference in islet mass between db/db groups appeared to
FIG. 3. The db/db-SGLT2
2/2 mice display improved b-cell function in vivo. A: Glucose infusion rates (GIR) required to maintain hyperglycemia
during 120-min clamp experiment. B: Changes in plasma glucose during the clamp in response to GIR in A. C: AUC calculations are shown for the
change in plasma glucose (D glucose) from baseline during the clamp. D: Changes in plasma insulin in response to changes in plasma glucose in B
(db/db-SGLT2
+/+ vs. db/db-SGLT2
2/2; P < 0.01). E: AUC calculation is shown for D insulin during glucose stimulation. F: Net change in plasma
insulin levels from baseline (D insulin) during the clamp (n =6 –9 per group). Data were analyzed by Student t test. Signiﬁcance between curves
was determined by one-way ANOVA. *P < 0.05, **P < 0.01. Data represent the mean 6 SEM.
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number (P = 0.22; Fig. 4D). There was no difference in
the frequency of Ki-67–positive b-cells between genotypes
(Fig. 4E and G), suggesting that b-cell proliferation rates
were not increased in the db/db-SGLT2
2/2 mice. However,
the frequency of TUNEL-positive b-cells was 64% less in
db/db-SGLT2
2/2 mice (Fig. 4F and G), indicating that rates
of cell death were slower. Thus, improvements in b-cell
function observed in vivo appeared to result from main-
tained b-cell mass due to reduced frequency of b-cell death.
DISCUSSION
Type 2 diabetes is characterized by impaired glucose-
stimulated insulin secretion, which is strongly associated
with hyperglycemia in rodent and human studies (8,9,
11,26). Chronic hyperglycemia may shift the balance of
b-cell proliferation and apoptosis toward cell death,
resulting in b-cell deﬁciency and impaired insulin secretion
(8,10,27). Although there seem to be some differences be-
tween rodents and humans with regard to the importance of
b-cell proliferation in response to hyperglycemia, human
autopsy studies have demonstrated a decline in b-cell mass
in individuals with type 2 diabetes that was associated with
increased b-cell death (9). A major ﬁnding of our study was
that reducing glucose toxicity in a model of extreme di-
abetes preserved islet mass and improved insulin secretion
in vivo. Increasing renal glucose excretion in db/db mice by
SGLT2 deletion produced beneﬁcial effects in glucose ho-
meostasis and, importantly, islet function.
The lack of difference in islet function during isolation/
perifusion studies described here suggested that the pri-
mary mechanism by which reduced glucose toxicity im-
proved glucose-stimulated insulin secretion was through
preservation of islet mass rather than a change in in-
dividual b-cell function. A similar effect was observed after
pharmacologic inhibition of SGLT2 in db/db and KK-A
y
mice for 12 and 9 weeks, where total pancreatic insulin
content and immunohistologic staining for insulin were
increased in treated mice (16,28). No human studies with
SGLT2 inhibitors have addressed islet function directly,
and so the potential for SGLT2 inhibition to preserve b-cell
FIG. 4. Pancreatic b-cell mass is increased in db/db-SGLT2
2/2 mice due to reduced frequency of cell death. A: Insulin secretion from isolated,
perifused islets in response to low/high glucose and KCl. B: Glucagon suppression during the same experiment performed in A. C: Relative b-cell
volume (islet area/pancreas area) determined from histologic analysis of pancreata. D: Islet number corrected by pancreas area. E: Frequency of
b-cell proliferation determined as the number of Ki67/insulin-positive cells per relative islet area. F: Frequency of b-cell death was calculated as
the number of TUNEL/insulin-positive cells per relative islet area. G: Representative images of histologic samples used for calculations in C–E.
Pancreata stained as follows: panel 1, hematoxylin and eosin (H&E) stain; panel 2, insulin stain; panel 3, Ki-67 stain. Arrow denotes a Ki-67–
positive cell; panel 4, TUNEL/insulin costain. Arrow denotes a TUNEL/insulin-positive cell. H&E viewed at original magniﬁcation 340, all others
at 3100. n =3 –7 per group. Data were analyzed by Student t test. *P < 0.05. Data represent the mean 6 SEM. (A high-quality digital representation
of this ﬁgure is available in the online issue.)
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remains to be determined.
Hyperglycemia in insulin-resistant or -deﬁcient models
has also been shown to contribute to peripheral insulin
resistance (12,29). Despite a 64% increase in the GIR re-
quired to maintain euglycemia in db/db-SGLT2
2/2 mice,
equivalent improvements in measured indices of insulin
sensitivity were not detected during euglycemic clamps.
There was no difference in whole-body or tissue-speciﬁc
glucose uptake, and endogenous glucose production was
modestly improved by 24% in db/db-SGLT2
2/2 mice. It
seems likely that unaccounted for differences in GIR could
result from glucosuria, but estimating acute glucosuria
during the clamp was technically difﬁcult. Furthermore,
db/db mice possess a complex metabolic phenotype and
insulin resistance stemming from multiple factors, including
hyperglycemia, hyperlipidemia, and hypercorticosteronemia
(30–32). An even modest improvement in insulin re-
sistance in this model suggests that reducing glucose
toxicity by renal glucose excretion may produce even
more beneﬁcial effects on insulin resistance under less
severe circumstances. In fact, inhibition of SGLT2 in ZDF
rats for 15 days improved insulin sensitivity (15).
In contrast to the subtle improvement in insulin sensi-
tivity, SGLT2 knockout markedly improved glucose in-
tolerance under HFD-induced, insulin-resistant conditions,
and reduced fasting plasma glucose and insulin levels. RC/
SGLT2
2/2 mice also displayed improved glucose tolerance
and reduced fasting plasma glucose, without hypoglyce-
mia. Interestingly, SGLT2 knockout resulted in sub-
stantially increased caloric intake. Whether this was
a response to mild, undetected hypoglycemia or for other
reasons remains to be determined. Of note, SGLT2 muta-
tions in humans that result in familial renal glucosuria
rarely cause hypoglycemia (33–35). Likewise, the incidence
of hypoglycemia during clinical trials of SGLT2 inhibitors
is extremely low (17–22).
Inhibition of SGLT2 has the potential to promote nega-
tive energy balance and, in turn, weight loss. The lack of
differences in plasma electrolytes, phosphate, BUN, cre-
atinine, and the BUN/creatinine ratio suggested that vol-
ume depletion did not account for the differences in body
weight. Lack of volume depletion in SGLT2
2/2 mice was
also noted in a recent study; however, no difference in
body weight was detected (6). Mice in the previous report
were studied at between 12 and 20 weeks of age, and
group sizes for the body weight data ranged from 6 to 10.
Here, mice were studied at 16 weeks, and the group size
for body weight data were 16 per group. The breadth of
ages cited in the previous report, as well as smaller group
sizes, may account for the discrepancy. In support of re-
duced body weight with loss of SGLT2 function, a recently
described SGLT2 mutant mouse with glucosuria similar to
that described here was also noted to have reduced body
weight (36).
In fact, evidence from the literature supports the notion
of reduced body weight with SGLT2 deletion. Short-term
studies of approximately 2 weeks have demonstrated no
effect of SGLT2 inhibition on body weight in ZDF rats
(14,15), whereas longer-term studies of 8 weeks or more
have found reductions in body weight in rodents and
humans (13,16,19–21). Glucosuria that produced weight
loss in humans ranged from 50 to 80 g/day, or 10–16% of
a 2,000 kcal/day diet (19,20). In SGLT2
2/2 mice, glucosuria
averaged 0.48 mg/day or 13% of the daily caloric intake of
WT mice in this study. Interestingly, feeding increased
about 20% in SGLT2
2/2 mice, suggesting that an isocaloric
diet would have a greater potential for weight loss during
SGLT2 deﬁciency. Previous studies in rodents have also
noted concomitant increases in feeding behavior and weight
loss during SGLT2 inhibition (13,16). Although RC/SGLT2
2/2
mice weighed 10% less than RC/WT mice, there was no sig-
niﬁcant difference in body weight after 4 weeks HFD, al-
though SGLT2
2/2 mice weighed about 6% less. RC and HFD
mice both had increased urine production during periods of
food intake, and there was overall less urine output and
glucosuria on the HFD compared with RC. Together, these
data suggest that SGLT2 activity is greatest in the post-
prandial setting and that inhibition will produce greater
weight loss on a carbohydrate-rich diet.
In conclusion, SGLT2 deletion in mice resulted in pro-
found glucosuria and compensatory behavioral adapta-
tions aimed at replacing water and calories lost in the
urine. SGLT2 knockout led to favorable reductions in
plasma glucose and insulin during HFD and in the context
of genetic obesity. Perhaps the most ominous complica-
tion of diabetes is loss of islet function, because this will
accelerate the deterioration of glucose homeostasis and
increase the exposure to glucose toxicity. Ablation of
SGLT2 in db/db mice prevented loss of b-cell mass and
thus preserved in vivo glucose-stimulated insulin secre-
tion, which partly accounted for the overall improvements
in glucose homeostasis. Taken together, these data sup-
port SGLT2 inhibition as a viable insulin-independent
treatment for type 2 diabetes.
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